Table 2.

Patients’ age and sex of adverse events occurring in CAR-T therapies performed in real clinical setting

EUDRAVIGILANCE							FAERS
	Age	Sex	Subtotal	%	Total	%		Age	Sex	Subtotal	%	Total	%
Tisagenlecleucel	2 months - 2 years	F	5	1.76	11	3.87	Tisagenlecleucel	2 months - 2 years	F	4	1.01	12	3.02
		M	5	1.76					M	5	1.26
		NA	1	0.35					NA	3	0.75
	3-11 Years	F	19	6.69	53	18.66		3-11 years	F	26	6.53	78	19.60
		M	31	10.92					M	48	12.06
		NA	3	1.06					NA	4	1.01
	12-17 Years	F	23	8.10	55	19.37		12-17 Years	F	25	6.28	60	15.08
		M	28	9.86					M	30	7.54
		NA	4	1.41					NA	5	1.26
	18-64 Years	F	39	13.73	93	32.75		18-64 Years	F	36	9.05	91	22.86
		M	47	16.55					M	51	12.81
		NA	7	2.46					NA	4	1.01
	65-85 Years	F	4	1.41	19	6.69		65-85 Years	F	4	1.01	24	6.03
		M	14	4.93					M	20	5.03
		NA	1	0.35					NA	0	0.00
	> 85 Years	F	0	0.00	0	0.00		> 85 Years	F	0	0	0	0.00
		M	0	0.00					M	0	0
		NA	0	0.00					NA	0	0
	Not Specified	F	13	4.58	53	18.66		Not Specified	F	26	6.53	133	33.42
		M	22	7.75					M	45	11.31
		NA	18	6.34					NA	62	15.58
		Total	284	100	284	100			Total	398	100	398	100
	Age	Sex	Subtotal	%	Total	%		Age	Sex	Subtotal	%	Total	%
Axicabtagene ciloleucel	2 months - 2 years	F	0	0	0	0.00	Axicabtagene ciloleucel	2 months - 2 years	F	0	0	0	0.00
		M	0	0					M	0	0
		NA	0	0					NA	0	0
	3-11 years	F	0	0	0	0.00		3-11 years	F	0	0	0	0.00
		M	0	0					M	0	0
		NA	0	0					NA	0	0
	12-17 Years	F	1	0.15	1	0.15		12-17 Years	F	0	0	0	0.00
		M	0	0					M	0	0
		NA	0	0					NA	0	0
	18-64 Years	F	92	13.47	277	40.56		18-64 Years	F	118	15.88	337	45.36
		M	165	24.16					M	208	27.99
		NA	20	2.93					NA	11	1.48
	65-85 Years	F	62	9.08	149	21.81		65-85 Years	F	66	8.88	202	27.19
		M	81	11.86					M	125	16.82
		NA	6	0.87					NA	11	1.48
	> 85 Years	F	1	0.15	2	0.30		> 85 Years	F	2	0.27	2	0.27
		M	1	0.15					M	0	0
		NA	0	0					NA	0	0
	Not Specified	F	39	5.71	254	37.19		Not Specified	F	40	5.38	202	27.19
		M	59	8.64					M	54	7.27
		NA	156	22.84					NA	108	14.54
		Total	683	100	683	100			Total	743	100	743	100.00